AHCLNSEAnlon Healthcare LimitedMediumNeutral
Announced Fri, 20 Mar · 13:32 IST

Anlon Healthcare Limited has informed the Exchange regarding 'Disclosure dated November 28, 2025, and February 27, 2026, regarding acquisition of stake in Bizotic Life Science Private Limited'.

Listed Co AcquisitionStrategic Transactions View source PDF

AHCL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+0.2%1-day move
₹11.28
prior close
₹11.64
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.4-0.4-1.5-1.6+0.2-0.7+2.9+2.0-1.5-0.2+25.4+28.5+17.7+41.8
Up moveDown movePending
AI summary

Anlon Healthcare Limited has completed the acquisition of a 56.67% equity stake in Bizotic Life Science Private Limited on March 20, 2026. This was done under a Share Purchase Agreement originally signed on November 28, 2025, and later amended on February 27, 2026, which extended the completion deadline to April 2, 2026. With this acquisition, Bizotic Life Science has become a subsidiary of Anlon Healthcare. The investment is in compliance with the applicable provisions of the Companies Act, 2013. Further transaction details were already disclosed in the earlier filing dated November 28, 2025.

Likely market impact

Bizotic Life Science is now a subsidiary of Anlon Healthcare, expanding the company's portfolio and giving it controlling interest in the target's operations. Shareholders should expect consolidation of Bizotic's financials into Anlon's results going forward.